Corrigendum to “Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023–January 2024” [Vaccine 42(19) (2024)]

Charlotte Lanièce Delaunay(Helicon Foundation), Esther Kissling, Mihaela Lazăr, Marlena Kaczmarek(European Centre for Disease Prevention and Control), Jesús Castilla(Instituto de Salud Pública de Navarra), Marine Maurel, Gergő Túri(Semmelweis University), Tove Samuelsson Hagey(Public Health Agency of Sweden), Violeta Ramos Marín(Consejería de Educación de la Junta de Castilla y León), Marie‐Anne Rameix‐Welti(Inserm), Gloria Pérez‐Gimeno(Instituto de Salud Carlos III), Vítor Borges(National Institute of Health Dr. Ricardo Jorge), Ana Paula Rodrigues(Microsoft (Brazil)), Frederika Dijkstra(National Institute for Public Health and the Environment), Adam Meijer(National Centre for Infectious Diseases), Aryse Melo(National Institute of Health Dr. Ricardo Jorge), Sanja Filipović(Hrvatski zavod za javno zdravstvo), Beatrix Oroszi, Ralf Dürrwald(IDT Biologika (Germany)), Luise Goerlitz(Robert Koch Institute), Sabrina Bacci(European Centre for Disease Prevention and Control), Charlene Bennett(University College Dublin), Neus Latorre‐Margalef(Public Health Agency of Sweden), Clara Mazagatos(Instituto de Salud Carlos III), Joan O’Donnell(Health Service Executive), Noémie Sève(Inserm), Iván Martínez‐Baz(Instituto de Salud Carlos III), Ivan Mlinarić(Hrvatski zavod za javno zdravstvo), Raquel Guiomar(National Institute of Health Dr. Ricardo Jorge), Mariëtte Hooiveld(Netherlands Institute for Health Services Research)
Cited by 0


Related Papers